

Special Issue

The Treatment of Cardiovascular Diseases in the Critically Ill

Message from the Guest Editor

Cardiovascular diseases (CVDs) are the leading cause of mortality and morbidity worldwide. In the Intensive Care Unit (ICU) setting, many causes of myocardial injury are common in critically ill patients, differentiating between forms of cardiovascular disease management in this special population. The intensivist doctor deals with new complex situations and has difficult decisions to make because the patient is already admitted to the ICU and multiple possible causes for raised troponin or ECG changes coexist.

This Special Issue on "The Treatment of Cardiovascular Diseases in the Critically Ill" welcomes original research articles and state-of-the-art reviews in this field. Papers should provide novel data or gather current knowledge regarding the differentiation between cardiovascular diseases in critically ill patients vs. patients with solely cardiovascular disease. A special focus on septic cardiomyopathy and Takotsubo syndrome along with a differentiation between acute coronary syndromes and arrhythmias in the ICU setting will be appreciated.

Guest Editor

Dr. Vasileios Vazgiourakis

Academic Intensive Care Unit, University Hospital of Larissa, Larissa, Greece

Deadline for manuscript submissions

30 September 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/217404

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).